Journal
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT
Volume 4, Issue -, Pages 83-91Publisher
CELL PRESS
DOI: 10.1016/j.omtm.2016.12.005
Keywords
-
Categories
Funding
- Conselho Nacional de Desenvolvimento Cientifico e Tecnologico [CNPq/405233/2016-7]
- Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior [CAPES/88887.094350/201500]
- Fundacao de Amparo a Pesquisa do Estado de Minas Gerais [FAPEMIG/02096-15]
Ask authors/readers for more resources
Lactococcus lactis is well documented as a promising candidate for development of novel oral live vaccines. It has been broadly engineered for heterologous expression, as well as for plasmid expression vector delivery, directly inside eukaryotic cells, for DNA vaccine, or as therapeutic vehicle. This work describes the characteristics of a new plasmid, pExu (extra chromosomal unit), for DNA delivery using L. lactis and evaluates its functionality both by in vitro and in vivo assays. This plasmid exhibits the following features: (1) a theta origin of replication and (2) an expression cassette containing a multiple cloning site and a eukaryotic promoter, the cytomegalovirus (pCMV). The functionality of pExu: egfp was evaluated by fluorescence microscopy. The L. lactis MG1363 (pExu: egfp) strains were administered by gavage to Balb/C mice and the eGFP expression was monitored by fluorescence microscopy. The pExu vector has demonstrated an excellent stability either in L. lactis or in Escherichia coli. The eGFP expression at different times in in vitro assay showed that 15.8% of CHO cells were able to express the protein after transfection. The enterocytes of mice showed the expression of eGFP protein. Thus, L. lactis carrying the pExu is a good candidate to deliver genes into eukaryotic cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available